Latest market price
20.02
-1.27-5.97%
OverviewShort InterestFilings
FTREQT87Fortrea Holdings Inc.·NASDAQ
20.02-5.97%
News
Down 6.0% — FTRE Q3 deep dive: margin gains, backlog reset, and early-phase expansion shape outlook (Yahoo).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
SEPN-1.82%$43.20ZYME+1.33%$28.99VCEL+0.62%$40.51MESO-4.09%$14.54SRPT-1.61%$18.32SLS-11.67%$8.55XERS-5.04%$10.17PVLA+0.12%$146.33
Snapshot
Index—P/E—EPS (ttm)-0.75Insider Own3.47%Shs Outstand95.10MPerf Week-9.90%
Market Cap2.02BForward P/E20.03EPS next Y1.06Insider Trans-7.16%Shs Float94.15MPerf Month9.74%
Enterprise Value2.91BPEG—EPS next Q—Short Float8.15%Perf Quarter12.41%
Income-68.00MP/S0.76EPS this Y66.56%Short Ratio4.93Perf Half Y74.79%
Sales2.67BP/B3.81EPS next Y25.35%ROA-2.51%Short Interest7.68MPerf YTD23.42%
Book/sh5.59P/C9.16EPS next 5Y25.15%ROE-12.81%52W High26.16 -23.47%Perf Year103.93%
Cash/sh2.32P/FCF16.20EPS past 3/5Y—ROIC2.34%52W Low8.55 134.15%Perf 3Y-21.50%
Dividend Est.—EV/EBITDA28.01Sales past 3/5Y-1.36% 1.08%Gross Margin18.54%Volatility6.31% 5.82%Perf 5Y—
Dividend TTM—EV/Sales1.09EPS Y/Y TTM—Oper. Margin1.57%ATR (14)1.44Perf 10Y—
Dividend Ex-Date—Quick Ratio0.97Sales Y/Y TTM-3.30%Profit Margin-2.58%RSI (14)46.39Recom2.54
Dividend Gr. 3/5Y—Current Ratio0.97EPS Q/Q133.33%SMA20-4.86%Beta2.02Target Price23.07
Payout0.00%Debt/Eq2.08Sales Q/Q-1.28%SMA504.99%Rel Volume1.76Prev Close21.29
Employees14,000LT Debt/Eq2.04EarningsFeb 25SMA20035.64%Avg Volume1.63MPrice20.02
IPO DateJun 20, 2023Option/ShortYes / YesEPS/Sales Surpr.28.94% 2.97%Net Debt/EBITDA8.54Volume2,873,286Change-5.97%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-30-26ReiteratedJefferiesHold$37 → $22
Oct-30-26ReiteratedTruist SecuritiesBuy$19 → $29
Oct-20-26ReiteratedUBSNeutral$22 → $24
Oct-15-26UpgradeDeutsche BankHold → Buy$20 → $25
Oct-06-26UpgradeBarclaysEqual Weight → Overweight$22 → $23
Sep-30-26InitiatedUBSNeutral$22
Jul-30-26ReiteratedDeutsche BankHold$18 → $20
Jul-30-26ReiteratedRobert W. Baird$21 → $23
Jul-30-26ReiteratedBarclaysEqual Weight$18 → $22
Jul-13-26ReiteratedMizuhoNeutral$15 → $16
Latest News· Times ET
Oct-31-26
Oct-31-2610:11PM
FTRE Q3 deep dive: margin gains, backlog reset, and early-phase expansion shape outlookYahoo
Oct-29-26
Oct-29-2601:02PM
What Fortrea (FTRE) Said on Its Q3 Earnings Callmarketbeat.com
12:29PM
Fortrea Holdings Inc. (FTRE) Q3 2026 Earnings Call Transcriptseekingalpha.com
08:46AM
Fortrea Holdings Inc. (FTRE) Q3 Earnings and Revenues Surpass Estimateszacks.com
06:30AM
Fortrea Reports Third Quarter 2026 Resultsglobenewswire.com
Oct-27-26
Oct-27-2607:00AM
Fortrea to Participate in Jefferies Global Healthcare Conferenceglobenewswire.com
Oct-26-26
Oct-26-2604:46PM
3 unpopular stocks that concern usYahoo
Oct-22-26
Oct-22-2604:05PM
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Developmentglobenewswire.com
11:02AM
Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?zacks.com
Oct-20-26
Oct-20-2609:35AM
9 Health Care Stocks Whale Activity In Today’s SessionBenzinga
Oct-19-26
Oct-19-2604:05PM
Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trialsglobenewswire.com
Oct-15-26
Oct-15-2601:10PM
3 Top Small-Cap Stocks With Market-Beating Momentumseekingalpha.com
02:34AM
Deutsche Bank Upgrades Fortrea Holdings to Buy, Raises Price Target to $25Benzinga
Oct-09-26
Oct-09-2606:59AM
3 Overrated Stocks We Think Twice AboutYahoo
04:46AM
MindWalk (NASDAQ:HYFT) & Fortrea (NASDAQ:FTRE) Head to Head Contrastdefenseworld.net
Company

Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue2,6682,7232,6962,843———
Cost of Goods Sold Incl. D&A2,1732,2982,1622,252———
Gross Profit495426534591———
Selling, General and Administrative Excl. Other410456561448———
Research and Development
0000———
Other Operating Expense430135111———
Operating Income42-31-16232———
Interest Expense819112470———
Unusual Expense
———————
Non-Operating Income (Expense)-13-861117———
Net Income Before Taxes-53-983-275-30———
Income Taxes163-31———
Consolidated Net Income-68-986-328-25———
Net Income From Continuing Operations-68-986-271-32———
Net Income-68-986-328-25———
EPS (Recurring)-0.75-10.81-3.67-0.04———
EPS (Basic, Before Extraordinaries)-0.75-10.81-3.67-0.04———
EPS (Diluted)-0.75-10.81-3.67-0.04———
EBITDA104-814-64137———
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio0.720.580.621.09———
Gross Margin18.5515.6419.8120.79———
Operating Margin1.57-1.14-6.011.13———
Net Margin-2.55-36.21-12.17-0.88———
Shares Outstanding96919089———
Market Capitalization1,9221,5701,6783,106———
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$28.50$22.82$17.14$11.46$5.78● Close Price0.00M1.05M2.10M3.15M4.20MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Morais Mark A.Chief Operating OfficerSep 09 '26Sale16.853,14953,06181,794Sep 10
Russell Carrie ElizabethInterim CAOSep 09 '26Sale16.852464,1452,384Sep 10
Morais Mark A.Chief Operating OfficerSep 08 '26Option Exercise0.007,157084,943Sep 10
Russell Carrie ElizabethInterim CAOSep 08 '26Option Exercise0.0085002,630Sep 10
Morais Mark A.Chief Operating OfficerAug 19 '26Sale18.194,89288,98577,786Aug 19
Morais Mark A.Chief Operating OfficerAug 18 '26Option Exercise0.0011,313082,678Aug 19
Thakral AnshulChief Executive OfficerAug 06 '26Sale18.11111,8572,026,284204,940Aug 07
Thakral AnshulChief Executive OfficerAug 05 '26Sale19.1699,8691,913,112316,797Aug 06
Thakral AnshulChief Executive OfficerAug 04 '26Option Exercise0.00416,6660416,666Aug 06
SANDERS MACHELLEDirectorAug 03 '26Sale18.019,700174,69736,399Aug 05
Smith David RossDirectorJul 20 '26Option Exercise0.006,598036,715Jul 27
SANDERS MACHELLEDirectorJun 10 '26Option Exercise0.0038,817046,099Jun 12
Smith David RossDirectorJun 10 '26Option Exercise0.0038,817048,361Jun 12
Pesicka Edward ADirectorJun 10 '26Option Exercise0.0038,817052,453Jun 12
Morais Mark A.Chief Operating OfficerJun 10 '26Sale16.824,67478,61771,365Jun 12
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.